PALLADIO BIOSCIENCES

palladio-biosciences-logo

Palladio Bio is a clinical-stage company developing transformative medicines for orphan diseases of the kidney. The company specializes in the fields of biotechnology, pharmaceutical. and therapeutics. Its products are designed for renal disease, kidney disease, and polycystic kidney disease. The company was founded in 2015 and headquartered in Horsham, Pennsylvania.

#SimilarOrganizations #People #Financial #Website #More

PALLADIO BIOSCIENCES

Social Links:

Industry:
Biotechnology Pharmaceutical Therapeutics

Founded:
2015-01-01

Address:
Horsham, Pennsylvania, United States

Country:
United States

Website Url:
http://www.palladiobio.com

Total Employee:
1+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
20 M USD

Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS AWS Global Accelerator


Similar Organizations

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

axcella-logo

Axcella

Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.


Current Advisors List

michele-ollier_image

Michele Ollier Board Member @ Palladio Biosciences
Board_member

sanford-zweifach_image

Sanford Zweifach Board Member @ Palladio Biosciences
Board_member

jonathan-edwards_image

Jonathan Edwards Board Member @ Palladio Biosciences
Board_member

Current Employees Featured

lorenzo-pellegrini_image

Lorenzo Pellegrini
Lorenzo Pellegrini CEO & founder @ Palladio Biosciences
CEO & founder

neil-shusterman_image

Neil Shusterman
Neil Shusterman Chief Medical Officer @ Palladio Biosciences
Chief Medical Officer

linda-hogan_image

Linda Hogan
Linda Hogan Chief Business Officer @ Palladio Biosciences
Chief Business Officer
2016-10-01

Founder


lorenzo-pellegrini_image

Lorenzo Pellegrini

Investors List

samsara-biocapital_image

Samsara BioCapital

Samsara BioCapital investment in Series B - Palladio Biosciences

osage-university-partners_image

OUP (Osage University Partners)

OUP (Osage University Partners) investment in Series B - Palladio Biosciences

roche-venture-fund_image

Roche Venture Fund

Roche Venture Fund investment in Series B - Palladio Biosciences

medicxi-ventures_image

Medicxi

Medicxi investment in Series B - Palladio Biosciences

medicxi-ventures_image

Medicxi

Medicxi investment in Series A - Palladio Biosciences

Official Site Inspections

http://www.palladiobio.com

  • Host name: 104.21.49.181
  • IP address: 104.21.49.181
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Palladio Biosciences"

Palladio Biosciences - Crunchbase Company Profile & Funding

Organization. Palladio Biosciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email โ€ฆSee details»

Palladio Biosciences - PitchBook

Palladio Biosciences General Information Description. Developer of novel therapeutics designed to offer medicines for orphan drug diseases of the โ€ฆSee details»

Palladio Biosciences - Craft

Palladio Biosciences is a company developing medicines for orphan diseases of the kidney. Its lead product, lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of โ€ฆSee details»

Palladio Biosciences - Contacts, Employees, Board Members, โ€ฆ

Organization. Palladio Biosciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of โ€ฆSee details»

Palladio Biosciences - Org Chart, Teams, Culture & Jobs - The Org

View Palladio Biosciences' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»

Palladio Biosciences - Funding, Financials, Valuation & Investors

Palladio Biosciences develops transformative medicines for orphan diseases of the kidney.See details»

Palladio Biosciences - VentureRadar

Similar Companies: AceLink Therapeutics USA Privately Held Founded in 2019, AceLink Therapeutics is an innovative biopharma startup focusing on developing safe and effective โ€ฆSee details»

Palladio Biosciences CEO and Key Executive Team | Craft.co

Palladio Biosciences's Chief Executive Officer & Director is Alex Martin. Other executives include Lorenzo Pellegrini, Founder, Director and Chief Operating Officer; Marella Thorell, Chief โ€ฆSee details»

Palladio Biosciences - Centessa Therapeutics (NASDAQ:CNTA)

Palladio Bio is a clinical stage company developing transformative medicines for orphan diseases of the kidney. The companyโ€™s lead drug is the vasopressin V2 receptor antagonist lixivaptan โ€ฆSee details»

Palladio Biosciences Receives FDA IND Clearance to โ€ฆ

May 8, 2018 Palladio Biosciences Receives FDA IND Clearance to Begin the ELISA Study, a Phase 2 Clinical Trial with Lixivaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)See details»

Palladio Biosciences Appoints Alex Martin Chief โ€ฆ

Aug 8, 2019 Palladio Biosciences, Inc. Linda Hogan, +1 908-294-8728 [email protected] Release Summary Palladio Biosciences Leadership Team expands with appointment of Alex Martin as CEO.See details»

Palladio Receives Orphan Drug Designation From The FDA For

Oct 4, 2017 NEWTOWN, Pa.--(BUSINESS WIRE)--Palladio Biosciences, Inc. (Palladio), a privately held biopharmaceutical company founded to develop medicines that make a โ€ฆSee details»

Palladio Biosciences Appoints Neil H. Shusterman, M.D., as Chief ...

Jan 3, 2019 Palladio Biosciences, Inc. Linda Hogan, +1-908-294-8728 [email protected] Release Summary Dr. Neil H. Shusterman joins Palladio Biosciences as Chief Medical OfficerSee details»

Palladio grabs $20M to take once-discarded drug through phase 3

Sep 25, 2020 Palladio Biosciences has raised a $20 million series B round. The financing, which attracted support from Roche Venture Fund and Medicxi, sets Palladio up to test its โ€ฆSee details»

Palladio Biosciences Formed to Develop Transformative Medicines โ€ฆ

May 23, 2017 Palladio Biosciences, Inc. Linda Hogan, +1 908-294-8728 [email protected] Release Summary Palladio Biosciences, newly formed start up, โ€ฆSee details»

Palladio Biosciences Announces Dosing of First ... - Pipelinereview

Dec 20, 2018 For more information, please visit www.palladiobio.com. About the PKD Foundation: The PKD Foundation is the only organization in the U.S. solely dedicated to โ€ฆSee details»

Palladio Biosciences Receives FDA IND Clearance to Begin the

May 8, 2018 Palladio Biosciences Receives FDA IND Clearance to Begin the ELISA Study, a Phase 2 Clinical Trial with Lixivaptan in Patients with Autosomal Dominant Polycystic Kidney โ€ฆSee details»

Palladio Biosciences Announces Dosing of First Patients with

Dec 18, 2018 Palladio Biosciences Announces Dosing of First Patients with Lixivaptan in ELiSA, a Phase 2 Clinical Study in Patients with Autosomal Dominant Polycystic Kidney Disease โ€ฆSee details»

Palladio Completes $20 Million Series B Financing - Business Wire

Sep 25, 2020 Linda Hogan Palladio Biosciences, Inc. 908-294-8728 [email protected]. Contacts. Linda Hogan Palladio Biosciences, Inc. 908-294-8728 [email protected]. Site โ€ฆSee details»

Palladio Biosciences Announces Dosing of First Patients with โ€ฆ

Dec 18, 2018 Palladio Biosciences Announces Dosing of First Patients with Lixivaptan in ELiSA, a Phase 2 Clinical Study in Patients with Autosomal Dominant Polycystic Kidney Disease โ€ฆSee details»

linkstock.net © 2022. All rights reserved